Lipella Pharmaceuticals INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OTC.Pink
Jonathan H. Kaufman, President, CEO, and Chairman of Lipella Pharmaceuticals Inc., has filed an Amendment No. 18 to Schedule 13D, indicating he is no longer a beneficial owner of more than five percent of the company's common stock.
OTC.Pink
Dr. Michael B. Chancellor, Chief Medical Officer and Director of Lipella Pharmaceuticals Inc., has filed an Amendment No. 9 to Schedule 13D, indicating he has ceased to be a beneficial owner of more than five percent of the company's common stock.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals CEO's Voting Control Shifts as SEC Declares Resale Registration Effective
Lipella Pharmaceuticals Inc. CEO Jonathan H. Kaufman's beneficial ownership filing reveals an updated stake of 8.0% and the termination of a significant proxy agreement with Spartan Capital Securities following the SEC's declaration of effectiveness for a resale registration statement.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals CEO Secures Irrevocable Proxy Over Shares Issued to Placement Agent
Lipella Pharmaceuticals Inc. has disclosed an irrevocable proxy granted by Spartan Capital Securities, LLC to CEO Dr. Jonathan Kaufman, giving him voting control over shares issued as compensation for advisory and placement agent services.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals CEO Secures Irrevocable Proxy Over Key Investor Shares, Consolidating Voting Control
Lipella Pharmaceuticals Inc. has disclosed an irrevocable proxy agreement granting its CEO, Dr. Jonathan Kaufman, voting control over a significant block of shares issued to Spartan Capital Securities, LLC, stemming from consulting and placement agent agreements.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals CEO Secures Irrevocable Proxy Over Key Shares from Spartan Capital
Lipella Pharmaceuticals Inc. has filed an Amendment No. 14 to its Schedule 13D, detailing an irrevocable proxy agreement granting CEO Dr. Jonathan Kaufman voting control over significant shares issued to Spartan Capital Securities, LLC.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals CEO Secures Irrevocable Proxy Over Key Shares, Bolstering Control Amidst Private Placement
Lipella Pharmaceuticals Inc. has filed an amendment to its Schedule 13D, revealing an irrevocable proxy granted by Spartan Capital Securities, LLC to CEO Dr. Jonathan Kaufman, giving him voting control over significant convertible preferred and warrant shares issued in recent agreements and a private placement.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals Insider Michael Chancellor Updates Beneficial Ownership to 7.9%
Dr. Michael B. Chancellor, Chief Medical Officer and a Director of Lipella Pharmaceuticals Inc., has updated his beneficial ownership stake to 7.9% of the company's common stock.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals Insider Jonathan Kaufman Updates Beneficial Ownership to 8.0%
Jonathan H. Kaufman, President and CEO of Lipella Pharmaceuticals Inc., has filed an Amendment No. 12 to his Schedule 13D, updating his beneficial ownership in the company to 8.0% of outstanding common stock.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals Officer Michael Chancellor Discloses 10% Beneficial Ownership Stake
Michael B. Chancellor, Chief Medical Officer and Director of Lipella Pharmaceuticals Inc., has updated his beneficial ownership to 10.0% of the company's common stock, totaling 209,640 shares.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals CEO Jonathan Kaufman Updates 10.1% Beneficial Ownership Stake
Jonathan H. Kaufman, President, CEO, and Chairman of Lipella Pharmaceuticals Inc., has updated his beneficial ownership to 10.1% of the company's common stock, as detailed in Amendment No. 11 to his Schedule 13D filing.
OTC.Pink
Michael B. Chancellor updates his beneficial ownership in Lipella Pharmaceuticals to 11.5% following a reverse stock split and adjustments to his holdings.
OTC.Pink
Jonathan H. Kaufman, a key executive at Lipella Pharmaceuticals, has updated his beneficial ownership in the company to 212,289 shares, representing 11.7% of the outstanding common stock.
OTC.Pink
SCHEDULE 13D/A: Lipella Pharmaceuticals CEO's Voting Control Shifts as Resale Registration Statement Becomes Effective
Jonathan H. Kaufman's beneficial ownership of Lipella Pharmaceuticals Inc. common stock remains at 16.2%, but his voting control over shares held by Spartan Capital Securities, LLC has terminated following the SEC's declaration of effectiveness for the company's Resale Registration Statement.
OTC.Pink
Lipella Pharmaceuticals Inc. CEO, Dr. Jonathan Kaufman, has secured an irrevocable proxy from Spartan Capital Securities, LLC, granting him voting control over a significant block of shares issued for advisory and placement agent services.